ArticleClinical rheumatology2026
Amyloidosis awareness and colchicine adherence in patients with familial Mediterranean fever: a cross-sectional study in an endemic region.
Article in Clinical rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionFamilial Mediterranean Fever (FMF) is the most common hereditary autoinflammatory disease, and secondary amyloidosis remains its most serious complication. We aimed to investigate amyloidosis awareness, colchicine adherence and related factors among FMF patients.
methodsIn this cross-sectional single-center study, patients with FMF completed a face-to-face questionnaire assessing amyloidosis awareness using structured questions and colchicine adherence through self-reported medication use. Demographic and clinical data were obtained from medical records. Factors associated with amyloidosis awareness and colchicine adherence were evaluated using univariate and multivariable analyses.
resultsA total of 185 patients were included; 64% were female. The median age was 38 years and disease duration was 13 years. Regular colchicine use was reported by 144 (78%) patients and was associated with awareness of its importance, older age, higher colchicine dose, and fewer attacks. Only 51 (27%) patients were completely or partially aware of amyloidosis, whereas 153 (83%) were aware of the risk of renal failure. Amyloidosis awareness was associated with younger age and higher education level. In multivariable analysis, regular colchicine use was independently associated with fewer attacks and a higher daily colchicine dose; while amyloidosis awareness was independently associated with awareness of the amyloidosis risk related to irregular colchicine use.
conclusionAwareness of amyloidosis remains insufficient among patients with FMF, although colchicine adherence was high. Targeted educational strategies may be needed to improve awareness of amyloidosis and its prevention. Key Points • Awareness of amyloidosis was limited (27%) and was associated only with awareness of the amyloidosis risk related to irregular colchicine use. • Treatment adherence is closely linked to higher colchicine dose and fewer attacks.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.